CN115466699A - 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 - Google Patents
熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 Download PDFInfo
- Publication number
- CN115466699A CN115466699A CN202211195400.3A CN202211195400A CN115466699A CN 115466699 A CN115466699 A CN 115466699A CN 202211195400 A CN202211195400 A CN 202211195400A CN 115466699 A CN115466699 A CN 115466699A
- Authority
- CN
- China
- Prior art keywords
- panda
- lactobacillus salivarius
- inflammatory bowel
- derived
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186869 Lactobacillus salivarius Species 0.000 title claims abstract description 82
- 208000025174 PANDAS Diseases 0.000 title claims abstract description 58
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 title claims abstract description 58
- 240000004718 Panda Species 0.000 title claims abstract description 58
- 235000016496 Panda oleosa Nutrition 0.000 title claims abstract description 58
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 235000013373 food additive Nutrition 0.000 claims abstract description 7
- 239000002778 food additive Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims description 27
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000003608 fece Anatomy 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960002160 maltose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229940073490 sodium glutamate Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 66
- 210000001072 colon Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 206010009887 colitis Diseases 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000003923 Protein Kinase C Human genes 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- 241000577483 Salmonella enterica subsp. enterica serovar Paratyphi B Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000037308 hair color Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 208000027503 bloody stool Diseases 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010057669 Colon injury Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了熊猫源唾液乳杆菌的应用,包括熊猫源唾液乳杆菌,及其在制备和/或治疗预防炎症性肠病药物中的应用、用于治疗和/或预防炎症性肠病的药物组合物、用于治疗和/或预防炎症性肠病的食品,用于预防和/或治疗炎症性肠病的保健品、用于治疗和/或预防炎症性肠病的食品添加剂,熊猫源唾液乳杆菌对炎症性肠病具有优异的抵抗力且无毒副作用,可用于治疗和预防炎症性肠病,具有重大应用价值。
Description
技术领域
本发明涉及微生物技术领域,具体涉及熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用。
背景技术
唾液乳杆菌为革兰氏染色阳性的无芽孢杆菌,广泛分布于含有碳水化合物的动植物发酵产品中,也见于温血动物的口腔、阴道和肠道内,在植物体表、乳制品、肉制品、啤酒、葡萄酒、果汁、麦芽汁、发酵面团、污水以及人畜粪便中,均可分离到。该菌分解糖的能力较强,分解蛋白质类的能力较低。行业公知唾液乳杆菌安全无毒,是一种可用于食用的益生菌,广泛用于泡菜、腌菜、酒和酸奶等食品的生产过程中。炎症性肠病是一组不明原因的慢性肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病。炎症性肠病的发病机制尚未阐明,目前认为是基因上易感人群对肠道共生微生物产生过度的先天或后天免疫反应所致。炎症性肠病目前尚缺乏有效的治疗手段,其治疗药物包括以下几类:氨基水杨酸类制剂、肾上腺糖皮质激素、免疫抑制剂、单克隆抗体、抗生素、微生态制剂等。传统药物如氨基水杨酸类制剂、糖皮质激素、免疫抑制剂等不良反应较多,而单克隆抗体药物又价格昂贵;微生态制剂因其对其他细菌具有明显的调节作用和较少的毒副作用而逐渐成为炎症性肠病治疗的新手段。
发明内容
本发明第一目的在于提供了熊猫源唾液乳杆菌,发现其在治疗和/或预防炎症性肠病和抑制致病性细菌上的作用,意在保护该熊猫源唾液乳杆菌及其在治疗和/或预防炎症性肠病中的应用,主要涉及将其应用于治疗炎症性肠病相关的药物组合物、食品、保健品及食品添加剂,其均包含所述熊猫源唾液乳杆菌。
为了解决现有治疗炎症性肠病的相关药物存在的不良反应多或价格昂贵的技术问题,第一方面,本发明提供了如下技术方案:
熊猫源唾液乳杆菌,所述唾液乳杆菌来源于大熊猫粪便,所述唾液乳杆菌的保藏号为 CGMCC No.24461,保藏于中国科学院微生物研究所。
第二方面,本发明还提供了熊猫源唾液乳杆菌在制备治疗和/或预防治疗炎症性肠病药物中的应用,该熊猫源唾液乳杆菌保藏于中国科学院微生物研究所,保藏号为CGMCCNo.24461。
上述的应用,所述药物含有药学有效剂量的熊猫源唾液乳杆菌和药学上可接受的载体。
上述的应用,所述熊猫源唾液乳杆菌的药学有效剂量为106-1010CFU/mL或106-1010CFU/g。
上述的应用,所述药学上可接受的载体为奶粉、乳糖、环糊精、麦芽糖、葡萄糖、甘油、谷氨酸钠、维生素C、甘露糖、半乳糖、甘露聚醇或甲基纤维素。
上述的应用,所述炎症性肠病为溃疡性结肠炎或克罗恩病。
第三方面,本发明还提供了一种用于治疗和/或预防炎症性肠病的药物组合物,所述药物组合物含有药学有效剂量的保藏号为CGMCC No.24461的熊猫源唾液乳杆菌,所述药物组合物中熊猫源唾液乳杆菌的剂量为106-1010CFU/mL或106-1010CFU/g。
第四方面,本发明还提供了一种用于治疗和/或预防炎症性肠病的食品,所述食品含有保藏号为CGMCC No.24461的熊猫源唾液乳杆菌。
第五方面,本发明还提供了一种用于治疗和/或预防炎症性肠病的保健品,所述保健品含有保藏号为CGMCC No.24461的熊猫源唾液乳杆菌。
第六方面,本发明还提供了一种用于治疗和/或预防炎症性肠病的食品添加剂,所述食品添加剂含有保藏号为CGMCC No.24461的熊猫源唾液乳杆菌。
本发明和现有技术相比,具有以下优点:
本发明发现的熊猫源唾液乳杆菌CGMCC No.24461分离于大熊猫粪便中,与已发现的唾液乳杆菌菌株差异显著,且首次发现该熊猫源唾液乳杆菌菌株能有效改善和抵御炎症性肠病相关症状,可为溃疡性结肠炎或克罗恩病提供治疗或预防,后续可利用本发明的唾液乳杆菌菌株制备成药物、食品、保健品或食品添加剂的形式,这些药物、食品、保健品或食品添加剂可用于预防和治疗炎症性肠病,具有重大应用价值。
附图说明
此处所说明的附图用来提供对本发明实施例的进一步理解,构成本申请的一部分,并不构成对本发明实施例的限定。在附图中:
图1为基于全基因组序列构建的系统进化树。该进化树中编号为Lactobacillussalivarius panda 103 是本发明的熊猫源唾液乳杆菌,图中的数字表示可信度(百分比),小于50的没有标示;
图2为本发明一实施例的各组小鼠DAI评分变化;
图3为本发明一实施例的各组小鼠结肠组织损伤HE染色图,其中,a、b为不同放大倍数的对照组;c、d分别为对应a、b的模型组;e、f分别为对应a、b的治疗组;
图4为本发明一实施例的各组小鼠MPO值;
图5为本发明一实施例的各组小鼠IL-β表达量;
图6为本发明一实施例的各组小鼠IL-6表达量;
图7为本发明一实施例的各组小鼠TNF-α表达量;
图8为本发明一实施例的各组小鼠体重变化;
图9为本发明一实施例的各组小鼠结肠长度变化;
图10为本发明一实施例的各组小鼠结肠组织损伤HE染色图,其中,a空白对照组;b为DSS模型组;c为唾液乳杆菌处理组;
图11为本发明一实施例的各组小鼠MPO值;
图12为本发明一实施例的各组小鼠IL-6表达量;
图13本发明一实施例的各组小鼠TNF-α表达量;
图14为本发明一实施例的抑制致病性大肠杆菌和乙型副伤寒沙门氏菌的抑菌圈图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白,下面结合实施例,对本发明作进一步的详细说明,本发明的示意性实施方式及其说明仅用于解释本发明,并不作为对本发明的限定。
实施例1
熊猫源唾液乳杆菌的分离、培养与鉴定
(1)样品收集和细菌培养
首先,将收集的新鲜的健康大熊猫粪便迅速转移到厌氧培养箱内,取10g新鲜粪便于 50mL离心管中,加入50mL PBS缓冲液,用无菌玻璃棒搅拌成匀浆;然后将其中杂质过滤收集菌液悬浊液,按照1/10的比例加入预脱氧培养基MRS中,放入厌氧培养室中,37℃培养48h;挑取单克隆接种到新的预脱氧MRS平板上传代培养。
(2)菌种鉴定
用无菌接种针挑取单个菌落于1.5mL离心管中,使用16S rRNA基因通用引物进行菌落 PCR。
使用的引物序列为:
27F(5’-AGAGTTTGATCCTGGCTCAG-3’)
1492R(5’-TACGGCTACCTTGTTACGACTT-3’)
PCR反应体系为:Master mix 12.5μL、上下游引物各1μL、模板DNA 1μL,补水至25μL。
反应程序为:94℃预变性4min,94℃变性1min,56℃退火1min,72℃延伸2min, 30个循环,72℃延伸10min。然后将PCR产物测序,并在RDP数据库进行比对,得到物种分类信息,经过16S rRNA基因序列比对鉴定该菌为细菌界,厚壁菌门,乳酸杆菌目,乳酸杆菌科,乳酸杆菌。
将得到的菌株经过全基因组测序,发现其包括一条环状染色体,其全长为1,721,267bp;还有一条环状质粒,其全长为159,036bp。将染色体全长序列与数据库中已存在的唾液乳杆菌进行序列比对和进化树分析,结果显示该菌株与唾液乳杆菌聚在一起,但与已知的唾液乳杆菌的基因组差异较大,如图1所示。对本实施例分离得到的唾液乳杆菌进行平均核酸一致性(average nucleotide identity,ANI)分析发现其与已知菌的基因组相似度最高的ANI为97.96。
上述熊猫源唾液乳杆菌被保藏于中国科学院微生物研究所,保藏地址:北京市朝阳区北辰西路1号院3号,保藏号为CGMCC No.24461,保藏日期为:2022年03月02日,分类命名为:唾液乳杆菌Lactobacillus salivarius。
实施例2
唾液乳杆菌缓解小鼠炎症性肠病的效果
本实施例以炎症性肠病的溃疡性结肠炎为例,效果实验具体包括以下:
选健康成熟,性别及年龄匹配的SPF小鼠30只,体质量23±1g,购买于成都达硕公司,饲养于SPF级动物房,在正常的实验室食物、饮水、光照的基础上适应环境饲养10天,喂食普通小鼠饲料,无其他排异反应,然后随机分成3组,每组10只。分组后采用5%DSS(dextran sulfate sodium,DSS,购自美国西格玛公司)溶液构建小鼠溃疡性结肠炎模型(表1):
表1小鼠分组情况
1、实验动物模型:
50g DSS加入1L蒸馏水中,充分溶解,配制成5%DSS溶液,每日新鲜配制。依据Cooper 等研究方法(Cooper,H.S.,Murthy,S.N.,Shah,R.S.,Sedergran,D.J.,1993.Clinicopathologic study of dextransulfatesodium experimentalmurinecolitis.LaboratoryInvestigation69,238–249.),模型组和治疗组的小鼠自由饮用5%DSS溶液代替饮用水;正常对照组的小鼠自由饮用市场上购买的矿泉水,无DSS。模型组和治疗组连续7天饲喂5%DSS溶液后,对治疗组开始给药,灌胃熊猫源唾液乳杆菌(保藏号CGMCCNo.24461),剂量设计为109CFU/mL的菌悬液200uL/ 只,每天灌胃1次,连续灌胃1周;模型组不给药。连续饮用DSS溶液7天后开始给药前, 3个组随机选择3只小鼠麻醉后眼眶取血,颈椎脱臼后处死,解剖取组织进行相关分析,验证模型是否构建成功;治疗一周后对所有小鼠麻醉后眼眶取血,颈椎脱臼后处死,解剖取组织进行相关分析。
2、小鼠疾病活动度积分的计算:
参照Hamamoto等标准(Murano M,Maemura K,Hirata I,Toshina K,Nishikawa T,Hamamoto N,Sasaki S,Saitoh O,Katsu K.Therapeutic effect ofintracolonicallyadministered nuclear factor kappa B(p65)antisenseoligonucleotide on mousedextran sulphate sodium(DSS)-induced colitis. ClinExp Immunol 2000;120:51-58),实验开始后,每日观察所有小鼠的体质量,收集其粪便分析大便性状和隐血情况,计算每只小鼠的疾病积分活动(DAI)积分,评估结肠炎活动程度。
结果如图2所示:
(1)正常对照组DAI评分始终稳定在零水平;
(2)模型小鼠(模型组和治疗组)在治疗组开始给药的第一天DAI评分显著高于对照组;
(3)模型组小鼠炎症逐渐加重;
(4)治疗组DAI评分也逐渐升高,但每天的DAI值显著低于对应时间点的模型组(P<0.05, T-test)。
以上结果表明模型小鼠构建成功,熊猫源唾液乳杆菌(保藏号CGMCC No.24461)治疗炎症性肠病小鼠效果显著。
3、病理学观察:
预冷生理盐水将大肠洗净,于大肠末端距离肛门1cm处剪取1cm大肠,4%多聚甲醛浸泡,石蜡包埋,切片,HE染色做病理检查。
结肠组织损伤HE染色参见图3,如a、b所示,空白对照组小鼠结肠粘膜结构完整,含大量杯状细胞,隐窝及腺体排列整齐;如c、d所示,模型组小鼠结肠粘膜结构完整性被严重破坏,肠壁明显增厚,肠上皮细胞及杯状细胞大量丢失,隐窝消失,粘膜层被大量中性粒细胞浸润,肌层明显增厚。说明模型小鼠建模成功。同时如e、f所示,治疗组小鼠结肠损伤相较于模型组呈现显著恢复状态,说明DSS造模成功后,熊猫源唾液乳杆菌(保藏号CGMCCNo.24461)能够减少结肠炎症产生的损伤。
4、实验观察指标:
(1)给药前7天,正常对照组小鼠毛色光滑、精神活跃、进食正常、无腹泻、无血便、大便球形;
(2)给药前7天内模型组小鼠毛色逐渐干枯、精神萎靡、反应迟钝、体型消瘦、食量降低、体质量减轻。整个实验过程中无小鼠死亡。
以上说明建模成功。
造模成功后予以唾液乳杆菌治疗1周,整个实验过程中无小鼠死亡,观察结果如下:
模型组小鼠食量降低,毛色干枯、拱背和拖尾,出现稀便,部分肛周可见血迹;治疗组食量增加,毛色逐渐有光泽,稀便次数显著减少,肛周没有血迹。
以上结果表明:唾液乳杆菌明显改善了炎症性肠病小鼠症状。
5、炎症指标
MPO值变化参考Hanai等的方法(Hanai H,Takeuchi K,Iida T,Kashiwagi N,Saniabadi AR, Matsushita I,et al.Relationship Between Fecal Calprotectin,Intestinal Inflammation,and Peripheral Blood Neutrophils in Patients withActive Ulcerative Colitis.2004;49(9):1438-43.)对小鼠的结肠炎炎症严重程度做出评价指标。参见图4,具体为各组小鼠给药第7天的炎症表现。模型组的MPO值高于空白组,而治疗组的MPO值低于模型组,表明唾液乳杆菌能够减轻结肠炎症浸润并且可以抑制由DSS引起的MPO值升高,减轻结肠炎症细胞浸润。该结果与病理结果相一致,表明唾液乳杆菌可以通过减少中性粒细胞的数量,减轻炎症反应,实现对小鼠结肠炎的缓解作用。
以上结果表明熊猫源唾液乳杆菌(保藏号CGMCC No.24461)治疗炎症性肠病小鼠效果显著。
血液细胞促炎因子IL-β、IL-6、TNF-α含量测定参考Kontny等的方法(Kontny E,MAActivation of protein kinase C(PKC)is critical forproduction of proinflammatory cytokines(TNFα,IL1β,IL6)[J].Immunology Letters,1997,56:409-410.)。对小鼠的结肠炎炎症严重程度做出评价指标。参见图5、图6以及图7,与正常对照组相比模型组小鼠结肠中促炎因子TNF-α、IL-1β和IL-6含量都出现增高现象,尤其是TNF-α和IL-1β的含量显著增高(P<0.05,T-test);与模型组相比,熊猫源唾液乳杆菌(保藏号CGMCC No.24461)降低了结肠中TNF-α、IL-1β和IL-6的含量(P<0.05,T-test)。说明DSS造模后小鼠体内促炎因子含量显著上升,熊猫源唾液乳杆菌(保藏号CGMCC No.24461)能够通过降低结肠中的促炎因子含量减少结肠炎症反应的产生。
以上结果表明熊猫源唾液乳杆菌(保藏号CGMCC No.24461)治疗炎症性肠病小鼠效果显著。
综上所述,实验结果充分表明熊猫源唾液乳杆菌(保藏号CGMCC No.24461)具有治疗炎症性肠病的作用。
实施例3
唾液乳杆菌预防小鼠炎症性肠病的效果
本实施例以溃疡性结肠炎为例,效果实验具体包括以下:
选健康成熟,性别及年龄匹配的SPF小鼠30只,体质量23±1g,购自成都达硕公司,饲养于SPF级动物房,在正常的实验室食物、饮水、光照的基础上适应饲养10天,喂食普通小鼠饲料,无其他排异反应,然后随机分成3组(空白照组、DSS模型组和唾液乳杆菌处理组),每组10只。
1、实验动物模型:
50g DSS加入1L蒸馏水中,充分溶解,配制成5%DSS溶液,每日新鲜配制。对唾液乳杆菌处理组灌胃熊猫源唾液乳杆菌(保藏号CGMCC No.24461),剂量设计为109CFU/mL 的菌悬液200uL/只,每天灌胃1次,连续灌14天;空白对照组和DSS模型组每只每天灌胃 200uL生理盐水,连续灌14天。灌胃14天结束后开始建模:DSS模型组和唾液乳杆菌处理组自由饮用5%DSS水溶液,空白对照组自由饮用市场上购买的矿泉水。建模7天后每组小鼠麻醉后眼眶取血,然后颈椎脱臼处死后进行解剖取组织进行相关分析。
2、造模期间体小鼠体重变化及实验观察指标
结果如图8所示:建模开始后,每日观察所有小鼠的体重变化。体重测量表明,空白对照组和唾液乳杆菌处理组小鼠在7天造模期间体重保持基本稳定或略有增长,而DSS模型组体重下降13.65%,第7天DSS模型组体重与空白组或唾液乳杆菌处理组差异显著(P<0.05, T-test)。对三组实验观察如下:
(1)给药7天内,空白对照组小鼠毛色光滑、精神活跃、进食正常、无腹泻、无血便、大便球形;
(2)给药7天内,DSS模型组小鼠大多出现严重便血、腹泻、蜷缩成堆、精神萎靡、毛色无光、大便松散、饮水量减少。整个实验过程中无小鼠死亡。
以上说明建模成功。
(3))给药7天内,唾液乳杆菌处理组小鼠未出现明显症状。
以上结果表明:熊猫源唾液乳杆菌明显抵御了炎症性肠病小鼠症状。
3、结肠长度测量
结果如图9所示:DSS模型组结肠平均长度为7.35cm,显著短于空白对照的8.65cm(P <0.01,T-test);唾液乳杆菌处理组小鼠的结肠长度与空白对照相比也有缩短的现象,但其结肠长度显著高于DSS模型组(P<0.05,T-test),说明熊猫源唾液乳杆菌有减缓炎症的作用。
以上结果表明模型小鼠构建成功,熊猫源唾液乳杆菌(保藏号CGMCC No.24461)预防炎症性肠病小鼠效果显著。
4、病理学观察:
预冷生理盐水将大肠洗净,于大肠末端距离肛门1cm处剪取1cm大肠,4%多聚甲醛浸泡,石蜡包埋,切片,HE染色做病理检查。
结肠组织损伤HE染色参见图10,如a所示,空白对照组小鼠结肠组织结构完整,黏膜层、黏膜下层、肌层和外膜分层明显,细胞排列整齐,未见病理变化。如b所示,DSS模型组小鼠结肠组织黏膜层受损较为明显,黏膜层变性坏死,坏死区域形态结构模糊,上皮明显脱落、缺失,固有层内肠腺结构基本不见,杯状细胞消失,坏死区域或萎缩肠腺周围可见淋巴细胞或中性粒细胞聚集,局部黏膜下层水肿伴轻微炎细胞浸润,表明具有严重的炎症反应。说明模型小鼠建模成功。如c所示,唾液乳杆菌处理组小鼠结肠组织黏膜层轻微受损,局部肠腺萎缩,体积减小,周围结缔组织内可见淋巴细胞聚集,表现出局部炎症反应,但严重程度与DSS模型组相比明显减轻。说明熊猫源唾液乳杆菌(保藏号CGMCC No.24461)能够预防DSS造成的结肠炎症的损伤。
5、炎症指标
MPO值变化参考Hanai等的方法(Hanai H,Takeuchi K,Iida T,Kashiwagi N,Saniabadi AR, Matsushita I,et al.Relationship Between Fecal Calprotectin,Intestinal Inflammation,and Peripheral Blood Neutrophils in Patients withActive Ulcerative Colitis.2004;49(9):1438-43.)对小鼠的结肠炎炎症严重程度做出评价指标。参见图11,具体为各组小鼠给药第7天的炎症表现。 DSS模型组的MPO值高于空白对照组(P<0.01,T-test),而唾液乳杆菌处理组的MPO值显著低于DSS模型组和空白对照组(P<0.001,T-test),表明唾液乳杆菌能够抵御由DSS引起的结肠炎症并且可以抑制MPO值升高。该结果与病理结果相一致,表明熊猫源唾液乳杆菌可以通过减少中性粒细胞的数量,减轻炎症反应,实现对小鼠结肠炎的预防作用。
以上结果表明熊猫源唾液乳杆菌(保藏号CGMCC No.24461)预防炎症性肠病小鼠效果显著。
血液细胞促炎因子IL-β、IL-6、TNF-α含量测定参考Kontny等的方法(Kontny E,MAActivation of protein kinase C(PKC)is critical forproduction of proinflammatory cytokines(TNFα,IL1β,IL6)[J].Immunology Letters,1997,56:409-410.)。对小鼠的结肠炎炎症严重程度做出评价指标。如图12和图13所示,DSS模型组相比于空白对照组小鼠结肠中促炎因子TNF-α和IL-6含量都出现增高现象,其中IL-6显著增加(P<0.05, T-test);而与DSS模型组相比,唾液乳杆菌处理组结肠中TNF-α和IL-6含量显著低于DSS 模型组(P<0.05,T-test),尤其是IL-6(P<0.01,T-test)。说明DSS造模后小鼠体内促炎因子含量显著上升,而熊猫源唾液乳杆菌(保藏号CGMCC No.24461)能够通过降低结肠中的促炎因子含量抵御结肠炎症反应的产生。
以上结果表明熊猫源唾液乳杆菌(保藏号CGMCC No.24461)抵御炎症性肠病小鼠效果显著。
综上所述,实验结果充分表明熊猫源唾液乳杆菌(保藏号CGMCC No.24461)具有预防炎症性肠病中的作用。
实施例4
熊猫源唾液乳杆菌(保藏号CGMCC No.24461)对致病性大肠杆菌和沙门氏菌的体外抑制作用
将熊猫源唾液乳杆菌(保藏号CGMCC No.24461)活化后接种至MRS液体培养基37℃培养24h后,调整菌体浓度至108CFU/mL,通过10,000r/min离心10min,然后将上清液经0.22μm微孔滤膜过滤,获得无细胞上清液(cell-free solution,CFS),采用牛津杯法测定熊猫源唾液乳杆菌(保藏号CGMCC No.24461)经发酵得到的无细胞上清液的抑菌能力,如图14 所示:熊猫源唾液乳杆菌(保藏号CGMCC No.24461)对致病性大肠杆菌(图14a)和乙型副伤寒沙门氏菌(图14b)均有显著的抑制作用,表明本发明的熊猫源唾液乳杆菌具有良好的抑制致病性大肠杆菌和乙型副伤寒沙门氏菌的能力,可能是该菌可治疗和/或预防炎症性肠病的一个原因。
本发明通过对熊猫源唾液乳杆菌(保藏号CGMCC No.24461),经由活体内及体外的相关实验证实,此熊猫源唾液乳杆菌可以改善并且预防炎症性肠病相关的溃疡性结肠炎症状,还可显著抑制致病性大肠杆菌和乙型副伤寒沙门氏菌的生长繁殖。因此,利用本发明的唾液乳杆菌可以制备成药物、食品、保健品或食品添加剂的形式来预防和治疗炎症性肠病,具有重大应用价值。
以上所述的具体实施方式,对本发明的目的、技术方案和有益效果进行了进一步详细说明,所应理解的是,以上所述仅为本发明的具体实施方式而已,并不用于限定本发明的保护范围,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.熊猫源唾液乳杆菌,其特征在于,所述唾液乳杆菌来源于大熊猫粪便,所述唾液乳杆菌的保藏号为CGMCC No.24461,保藏于中国科学院微生物研究所。
2.一种如权利要求1所述的熊猫源唾液乳杆菌在制备和/或治疗预防炎症性肠病药物中的应用,其特征在于,所述药物含有药学有效剂量的所述熊猫源唾液乳杆菌和药学上可接受的载体。
3.根据权利要求2所述的应用,其特征在于,所述熊猫源唾液乳杆菌的药学有效剂量为106-1010CFU/mL或106-1010CFU/g。
4.如权利要求2所述的应用,其特征在于,所述药学上可接受的载体为奶粉、乳糖、环糊精、麦芽糖、葡萄糖、甘油、谷氨酸钠、维生素C、甘露糖、半乳糖、甘露聚醇或甲基纤维素。
5.如权利要求2-4任一项所述的应用,其特征在于,所述炎症性肠病为溃疡性结肠炎或克罗恩病。
6.一种用于治疗和/或预防炎症性肠病的药物组合物,其特征在于,所述药物组合物含有药学有效剂量的保藏号为CGMCC No.24461的熊猫源唾液乳杆菌,所述药物组合物中熊猫源唾液乳杆菌的药学有效剂量为106-1010CFU/g或106-1010CFU/mL。
7.一种用于治疗和/或预防炎症性肠病的食品,其特征在于,所述食品含有保藏号为CGMCC No.24461的熊猫源唾液乳杆菌。
8.一种用于治疗和/或预防炎症性肠病的保健品,其特征在于,所述保健品含有保藏号为CGMCC No.24461的熊猫源唾液乳杆菌。
9.一种用于治疗和/或预防炎症性肠病的食品添加剂,其特征在于,所述食品添加剂含有保藏号为CGMCC No.24461的熊猫源唾液乳杆菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211195400.3A CN115466699B (zh) | 2022-09-28 | 2022-09-28 | 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211195400.3A CN115466699B (zh) | 2022-09-28 | 2022-09-28 | 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115466699A true CN115466699A (zh) | 2022-12-13 |
CN115466699B CN115466699B (zh) | 2023-03-31 |
Family
ID=84335362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211195400.3A Active CN115466699B (zh) | 2022-09-28 | 2022-09-28 | 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115466699B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116200313A (zh) * | 2023-04-07 | 2023-06-02 | 西南科技大学 | 一株唾液乳杆菌及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016554A1 (fr) * | 2000-08-25 | 2002-02-28 | Wakamoto Pharmaceutical Co.,Ltd. | Produits probiotiques contenant une bacterie de l'acide lactique |
WO2004069178A2 (en) * | 2003-01-30 | 2004-08-19 | Biogaia Ab | Anti-inflammatory activity from lactic acid bacteria |
CN102373162A (zh) * | 2010-08-09 | 2012-03-14 | 生展生物科技股份有限公司 | 唾液乳酸杆菌(Lactobacillus salivarius)M6及含有该唾液乳酸杆菌M6的抑菌组合物 |
WO2013014293A1 (en) * | 2011-07-27 | 2013-01-31 | University College Cork - National University Of Ireland, Cork | Anitmicrobial peptide produced by intestinal lactobacillus salivarius |
CN105770355A (zh) * | 2016-03-17 | 2016-07-20 | 青岛根源生物技术集团有限公司 | 一种预防肉鸡坏死性肠炎的复合制剂及其应用 |
WO2017034460A1 (en) * | 2015-08-25 | 2017-03-02 | Shahram Aghaibeik-Lavasani | Composition and method for treatment and prophylaxis of intestinal infection and inflammation |
EP3741218A1 (en) * | 2019-05-21 | 2020-11-25 | Probisearch, S.L.U. | Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets |
FR3112557A1 (fr) * | 2020-07-20 | 2022-01-21 | Lesaffre Et Compagnie | Combinaison de souches de lactobacilles et son utilisation en sante animale |
EP4032536A1 (en) * | 2021-01-26 | 2022-07-27 | Probisearch, S.L.U. | Probiotic composition for infants and its uses |
-
2022
- 2022-09-28 CN CN202211195400.3A patent/CN115466699B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016554A1 (fr) * | 2000-08-25 | 2002-02-28 | Wakamoto Pharmaceutical Co.,Ltd. | Produits probiotiques contenant une bacterie de l'acide lactique |
WO2004069178A2 (en) * | 2003-01-30 | 2004-08-19 | Biogaia Ab | Anti-inflammatory activity from lactic acid bacteria |
CN102373162A (zh) * | 2010-08-09 | 2012-03-14 | 生展生物科技股份有限公司 | 唾液乳酸杆菌(Lactobacillus salivarius)M6及含有该唾液乳酸杆菌M6的抑菌组合物 |
WO2013014293A1 (en) * | 2011-07-27 | 2013-01-31 | University College Cork - National University Of Ireland, Cork | Anitmicrobial peptide produced by intestinal lactobacillus salivarius |
WO2017034460A1 (en) * | 2015-08-25 | 2017-03-02 | Shahram Aghaibeik-Lavasani | Composition and method for treatment and prophylaxis of intestinal infection and inflammation |
CN108135948A (zh) * | 2015-08-25 | 2018-06-08 | 免疫生物技术医疗瑞典公司 | 用于治疗和预防肠感染和炎症的组合物和方法 |
CN105770355A (zh) * | 2016-03-17 | 2016-07-20 | 青岛根源生物技术集团有限公司 | 一种预防肉鸡坏死性肠炎的复合制剂及其应用 |
EP3741218A1 (en) * | 2019-05-21 | 2020-11-25 | Probisearch, S.L.U. | Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets |
FR3112557A1 (fr) * | 2020-07-20 | 2022-01-21 | Lesaffre Et Compagnie | Combinaison de souches de lactobacilles et son utilisation en sante animale |
EP4032536A1 (en) * | 2021-01-26 | 2022-07-27 | Probisearch, S.L.U. | Probiotic composition for infants and its uses |
Non-Patent Citations (4)
Title |
---|
PIAZA-DIAZ等: "Immune-Mediated mechanisms of action of probiotics and synbiotics in treating pediatric intestinal diseases" * |
张懋;刘颂蕊;张泽钧;洪明生;黄文俊;岳婵娟;刘礼;侯蓉;彭西;: "小熊猫源大肠杆菌病的病理诊断与病原鉴定" * |
王黎明等: "熊猫源唾液乳杆菌的分离鉴定及部分生物学特性分析" * |
魏振: "犊牛源乳酸菌对大肠杆菌造成的小鼠肠道炎性损伤保护作用效果的研究" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116200313A (zh) * | 2023-04-07 | 2023-06-02 | 西南科技大学 | 一株唾液乳杆菌及其应用 |
CN116200313B (zh) * | 2023-04-07 | 2023-11-21 | 西南科技大学 | 一株唾液乳杆菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115466699B (zh) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110122877B (zh) | 鼠李糖乳杆菌及其用途 | |
CN114107134B (zh) | 一株侧孢短芽孢杆菌及其应用 | |
CN114657084B (zh) | 一种缓解溃疡性结肠炎的长双歧杆菌及其应用 | |
CN116083325B (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
CN112481175B (zh) | 一株能预防和缓解溃疡性结肠炎的鼠李糖乳杆菌及其应用 | |
CN111996153A (zh) | 一种短双歧杆菌及其应用 | |
CN113755409B (zh) | 一种缓解胰岛素抵抗的长双歧杆菌及其应用 | |
CN113249280A (zh) | 一种嗜热链球菌stn26、菌粉及在降尿酸产品中的应用 | |
CN111117925B (zh) | Anaerostipes sp B2131菌及其在炎症性肠病中的应用 | |
CN115466699B (zh) | 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 | |
CN114672436B (zh) | 一株嗜酸乳杆菌及其应用 | |
CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
CN116731929A (zh) | 一株发酵粘液乳杆菌zs40及其应用 | |
CN113797232B (zh) | 具有缓解胰岛素抵抗功能的组合物及其应用 | |
CN114686405A (zh) | 一株具有减少脂肪和缓解高血糖,调节肠道免疫力的两歧双歧杆菌及其应用 | |
CN117264814A (zh) | 一种对消化道疾病具有预防治疗效果的鼠李糖乳酪杆菌 | |
CN116925980A (zh) | 一株缓解鼠伤寒沙门氏菌感染的格氏乳杆菌及其应用 | |
CN117143765A (zh) | 一株调控肠道稳态缓解顽固性便秘的长双歧杆菌长亚种及其应用 | |
CN116694534A (zh) | 一种长双歧杆菌sx-1326及其应用 | |
CN115873765A (zh) | 一株类肠膜魏斯氏菌MbWp-1及其产品与应用 | |
CN116019839A (zh) | 乳酸肠球菌jdm1在制备预防或治疗炎症性肠病的药物中的应用 | |
CN110079477B (zh) | 一株防治鸡白痢沙门氏菌病的植物乳杆菌及其制剂和应用 | |
CN117701477B (zh) | 一株副干酪乳酪杆菌及其在改善肠道疾病中的应用 | |
CN118165891B (zh) | 一种能够缓解腹泻的瑞士乳杆菌及其应用 | |
CN118064317A (zh) | 一株改善泻剂结肠的副干酪乳酪杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |